Joanne Mallinson is currently working as a post-doctoral research fellow in the School of Biomedical Sciences at the University of Nottingham. She is continuing his work on statin induced muscle myopathy and following on from a previous post-doctoral position within the same research group in which we collaborated with AstraZeneca Ltd. Statins are used clinically for cholesterol reduction, but statin therapy is associated with myopathic changes through a poorly defined mechanism. From his work with Astrazeneca, we concluded that simvastatin administration impaired PI3k/Akt signalling, and upregulated FOXO transcription factors and downstream gene targets known to be implicated in proteasomal and lysosomal mediated protein breakdown, muscle carbohydrate oxidation, oxidative stress and inflammation in an in vivo model of statin induced myopathy. These findings have now formed the basis of a study looking at statin muscle myopathy in humans, sponsored by the Dunhill Medical Trust, in which we aim to determine the mechanisms involved in statin myopathy in order to find a prevention or treatment for this condition.
For further details: Joanne Mallinson